FINWIRES · TerminalLIVE
FINWIRES

ASX:AXE

6 stories mentioning ASX:AXEUpdated 4d ago

Every FINWIRES story that references ASX:AXE, newest first.

Asia

Archer Materials Says Blood Collection Study Identifies Method With Low Levels of Hemolysis

Archer Materials (ASX:AXE) said an early-stage blood collection study for the development of its potassium biosensor identified a capillary blood collection approach that produced low levels of hemolysis broadly comparable with conventional venous blood collection, according to a Thursday Australian bourse filing.Hemolysis, where red blood cells are damaged during or after blood collection, can release additional potassium into the sample and potentially result in an artificially elevated potassium reading.The study involved 20 participants, per the filing. The extent of hemolysis associated with each collection approach was assessed in the laboratory. The firm said it will use the findings to further develop how blood is collected, processed and presented to the biosensor.Archer Materials' shares rose past 2% in recent trading on Thursday.

ASX:AXE
Asia

Archer Materials Achieves Full-Wafer Manufacturing Runs of Refined 12CQ Quantum Chip Key Components, Shares Jump 4%

Archer Materials (ASX:AXE) said it achieved full-wafer manufacturing runs of its refined 12CQ quantum chip key components in the June quarter, according to a Thursday Australian bourse filing.It demonstrated proof-of-concept performance for its quantum neural network relating to fraud detection in both simulation and quantum hardware applications.Its shares rose 4% in recent trading on Thursday.

ASX:AXE
Asia

Archer Materials to Raise AU$7 Million Through Placement, AU$3 Million Via Share Purchase Plan

Archer Materials (ASX:AXE) secured investor commitments for a dual-tranche placement to raise a gross AU$7 million through the issuance of about 25.9 million new shares at a price of AU$0.27 each, according to a Friday filing with the Australian bourse.The first tranche aims to raise about AU$6.9 million through the issuance of about 25.4 million shares. The second tranche is subject to shareholder approval and is geared toward investors that include members of the company's board and management, targeting about AU$140,000 before costs.Archer Materials also plans to launch a non-underwritten share purchase plan at the same price for eligible shareholders in Australia and New Zealand to generate up to AU$3 million.The company plans to use the proceeds to support a recent quantum compute agreement with US-listed IonQ, and for general working capital.The company's shares were down nearly 2% in recent Friday trade.

ASX:AXE
Asia

Archer Materials Signs Three-Year Quantum Compute Agreement With US-Listed IonQ

Archer Materials (ASX:AXE) entered into a quantum compute agreement with US-listed IonQ, providing Archer and its customers access to the IonQ Quantum Cloud for applications in defense, artificial intelligence, mining and resources, healthcare, and scientific research, according to a Wednesday Australian bourse filing.The company said the agreement has an initial term of three years, with Archer to pay IonQ $250,000 on signing and $250,000 every six months thereafter for a total of $1.5 million, in exchange for access to IonQ's Quantum Cloud on an IonQ Forte-class system and subsequently the IonQ Tempo-class system, along with quantum simulator access and expert advisory and consulting services.Under the agreement, Archer will build on its proprietary quantum applications via software and algorithm development, with the parties collaborating to assess the deployment of an IonQ quantum computer in Australia to establish a sovereign quantum computing capability onshore, the filing added.

ASX:AXE
Asia

Archer Materials Advances Biosensor Medical Device Program to Beta Prototype Stage, Shares Jump 3%

Archer Materials (ASX:AXE) advanced to the next stage of product development via the construction of its beta prototype Biosensor platform suitable for preclinical validation, after its integrated alpha prototype medical device achieved clinical-grade potassium sensing accuracy, according to a Friday Australian bourse filing.It plans to develop multiple versions of the beta prototype. The first beta prototype system is expected to become available for testing in the coming months. Early feasibility testing for monitoring lithium levels in blood is underway.Additional optimization and validation are planned throughout the second half of the year, with the target of a fully optimized beta prototype for use in trials in 2027.Its shares climbed 3% in recent trading on Friday.

ASX:AXE
Asia

Archer Materials Advances Quantum Device Technology Toward Wafer-Scale Manufacturing; Shares Jump 9%

Archer Materials (ASX:AXE) is progressing its qubit technology beyond laboratory-scale devices and beginning to work toward wafer-scale manufacturing using semiconductor industry-standard processes, according to a Tuesday Australian bourse filing.Recent development efforts are focused on refining the underlying device structures and fabrication processes, the filing said. The company completed multiple device design, fabrication, and testing cycles.Archer Materials' shares jumped nearly 9% in recent trading on Tuesday.

ASX:AXE

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:AXE in your portfolio
WheelAI
WheelAI
Analyze ASX:AXE options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:AXE